The European Medicines Agency (EMA), which is oversees the scientific evaluation, supervision and safety of medicines in the European Union, will scale back activities through 2019 due to significant staff loss when it moves from London to Amsterdam in March 2019 as a result of Brexit. Some of the areas that could be affected include the agency's work at the international level on supply chain integrity, antimicrobial resistance, vaccines, and clinical data analysis. Continue reading ->
Or they should be. That’s the conclusion of a recent study published in the medical journal Vaccine. The study focused on political views of parents in the state of California, who had chosen not to vaccinate their nursery-school aged children. And it tracked the number of parents who had filed personal belief exemptions (PBEs), applications for permission to avoid vaccinations over a 5-year period to 2015. A disproportionate number of parents filing such forms were from Republican or conservative neighbourhoods, according to researcher Kevin A Estep, from the health administration and policy program at the university. Continue reading ->
Using flexibilities in the World Trade Organization Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) has long been an issue of the developing world. But policymakers gathered at a meeting on access to health in Brussels today said there was an urgent need for European Union countries, too, to make more use of flexibilities. Continue reading ->
AIDS activists, health activists and civil society organizations in Brazil and Argentina are pushing back against the negative effects of the planned free trade agreement between the Mercosur countries and the European Union. The EU-Mercosur negotiations might be the best chance as of now to advance an intellectual property agenda that is more favourable to access to health, says Pedro Villardi, coordinator on IP policy issues at the Associação Brasiliera Interdisciplinar de Aids Observatorio National de Politicas de Aids (ABIA). Continue reading ->
Achieving a high percentage of universal health coverage often does not translate into a high quality of health systems, according to speakers at the opening of the Geneva Health Forum. While in developed countries people are demanding better quality, the expectations of people living in low and middle-income countries need to be raised, they said. Another panel looked at the use of big data and mathematical modelling as ways to improve health systems, including Facebook monitoring. Continue reading ->
Nobel Prize winner Sir John Sulston passed away on 6 March at the age of 75, and was widely remembered in the press and scientific circles, celebrating his research, his wisdom, and his leadership of the landmark Human Genome Project. Intellectual Property Watch recalls his visionary warning and advice a decade ago about the intellectual property system, investment, and science that is still valuable today. Continue reading ->
Pharmaceutical R&D constantly leads to the generation of new intellectual property (IP), from clinical trial data to libraries of promising compounds. Not all IP assets generated by a company are used in their future R&D. When this happens, companies can choose instead to share them with other third-party researchers, under licensing agreements. The Access to Medicine Foundation has worked with BIO Ventures for Global Health (BVGH) to develop a framework for identifying which IP assets are most difficult for companies to share, yet most likely to speed up R&D of the medicines and vaccines needed by people living in low- and middle-income countries (LMICs), write Clarke B. Cole and Katie Graef. Continue reading ->